Trevi Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(Amounts in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities: | ||
| Net loss | $(29,065) | $(29,152) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,247 | 2,327 |
| Write off of deferred offering costs | 390 | — |
| Operating lease right-of-use assets | 377 | — |
| Accretion/accrual of term loan discounts and debt issuance costs | 180 | 520 |
| Depreciation and amortization | 123 | 43 |
| Loss on disposal of property, equipment and leasehold improvements | 10 | — |
| Accretion of available-for-sale marketable securities, net | (2,125) | (829) |
| Change in fair value of term loan derivative liability | — | 147 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,850) | (601) |
| Accounts payable | (1,049) | 9 |
| Accrued expenses and other liabilities | 52 | (639) |
| Net cash used in operating activities | (31,710) | (28,175) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 69,497 | 19,001 |
| Purchases of available-for-sale marketable securities | (9,932) | (126,215) |
| Purchases of property, equipment and leasehold improvements | (137) | (159) |
| Net cash provided by (used in) investing activities | 59,428 | (107,373) |
| Financing activities: | ||
| Proceeds from at-the-market sales, net of commissions | 1,710 | — |
| Proceeds from exercises of stock options | 74 | 139 |
| Proceeds from employee stock purchase plan | 68 | 56 |
| Repayments of term loan, term loan final fee and prepayment premium | (9,409) | (5,833) |
| Payments of offering costs | (258) | (226) |
| Payments of finance lease | (95) | — |
| Proceeds from sale of common stock and warrants in public offering and private placement, net of issuance costs | — | 105,410 |
| Proceeds from exercises of warrants | — | 11,782 |
| Payments of financing costs of term loan | — | (21) |
| Net cash (used in) provided by financing activities | (7,910) | 111,307 |
| Net increase (decrease) in cash and cash equivalents | 19,808 | (24,241) |
| Cash and cash equivalents at beginning of period | 12,589 | 36,830 |
| Cash and cash equivalents at end of period | $32,397 | $12,589 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $(331) | $(594) |
| State research tax credits exchanged for cash | $55 | $— |
| Supplemental disclosure of non-cash financing activities: | ||
| Offering costs included in accrued expenses | $— | $15 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.